Marc's work sits at the intersection of technical depth, AI product development, and commercial strategy. He has developed and launched eight CE-marked AI-driven biomarkers for oncology, achieved FDA clearance for an AI imaging platform, and holds a US patent for AI-driven biomarker detection. He supports companies developing clinically relevant and technically demanding products, particularly where AI, evidence, product direction, and regulatory requirements need to be brought into sharp alignment. His perspective is especially valuable for businesses in healthtech, medtech, and diagnostics where scientific and AI credibility are commercial prerequisites.
Marc leads GoldWhite's life sciences and health-tech practice. He brings over a decade of experience spanning pharmaceutical R&D, AI-driven diagnostics, clinical biomarker strategy, and regulatory affairs.
As Director of Translational Sciences at a leading global pharmaceutical company, Marc leads enterprise-wide precision medicine strategies across multiple therapeutic areas, partnering with R&D, commercial, and regulatory teams to accelerate drug development. He has developed strategies for clinical trials ranging from Phase 1b to Phase 3 across immunology and fibrosis.
Prior to this, Marc was Senior Product Owner at an AI pathology company in New York and London, where he launched eight CE-marked AI-driven biomarkers for oncology. At a UK medical imaging company, he led new indications strategy and achieved FDA clearance and CE marking for an AI imaging platform, managing a cross-functional team of twenty. He has also served as a Policy Advisor to the Cabinet Office Open Innovation Team.
Marc holds a PhD in Clinical Neuroscience from Imperial College London, where his research focused on the blood-brain barrier in chronic traumatic encephalopathy. He holds an MSc in Neuroscience from King's College London and a BA in Psychology and Behavioural Neuroscience from McGill University. He is a published researcher with work appearing in Brain, Nature Communications, the Journal of Magnetic Resonance Imaging, and Acta Neuropathologica, and is a named inventor on a US patent for AI-driven biomarker detection.
The gap between a working prototype and a product generating revenue is wider than most founders expect, and better science rarely closes it. Five lessons from taking health-tech products through regulatory clearance and into the market.
A practical walkthrough of MDR, IVDR, FDA 510(k), and the EU AI Act for founders building AI-driven medical devices. What regulators need to see, and how to prepare before formal engagement begins.
Biomarker strategy is one of the most consequential decisions in early-stage drug development and one of the most commonly deferred. A practical guide to what to validate, how to sequence the work, and how to build a biomarker narrative that holds up under investor and regulatory scrutiny.
Every GoldWhite engagement is led by a director. Book 30 minutes and mention you would like to speak with Marc.
Book a Call →